756437-41-9

Basic information

• Product Name: 5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE
• Synonyms: 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one(HCl salt);5,6,7,8-Tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one hydrochloride;5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one(SALTDATA: 1.65HCl 1.5H2O);3-d]pyriMidin-4(3H)-one(HCl salt);3H,4H,5H,6H,7H,8H-pyrido[4,3-d]pyriMidin-4-one hydrochloride;5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE HCL;5,6,7,8-Tetrahydropyrido[4,3-d]pyrimidin-4-one;5,6,7,8-Tetrahydro-3H-pyrido[4,3-d]pyrimidin-4-one
• CAS NO: 756437-41-9
• Molecular Formula: C₇H₉N₃O
• Molecular Weight: 151.17
• Product Categories: CHIRAL CHEMICALS
• Mol File: 756437-41-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE(756437-41-9)
• EPA Substance Registry System: 5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE(756437-41-9)

Safety Data

• Hazardous Substances Data: 756437-41-9(Hazardous Substances Data)

Usage

General Description

5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE is a compound with the chemical formula C8H10N2O, and it is a heterocyclic organic compound. This chemical is a derivative of pyrimidine and it is often used in pharmaceutical research as a potential drug candidate. It has been studied for its potential biological activities, such as anti-inflammatory, anti-cancer, and anti-viral properties. 5,6,7,8-TETRAHYDROPYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE has also been investigated for its potential as a central nervous system depressant and could potentially be used as a sedative or tranquilizer. Its molecular structure and properties make it a subject of interest in the development of new pharmaceutical drugs.

InChI:InChI=1/C7H9N3O.ClH/c11-7-5-3-8-2-1-6(5)9-4-10-7;/h4,8H,1-3H2,(H,9,10,11);1H

Upstream product

• 1454-53-1 ethyl 1-benzyl-4-oxopiperidine-3-carboxylate hydrochloride 
• 109229-22-3 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one 

Downstream Products

• 1332455-31-8 C₂₀H₁₇N₃O₂ 
• 1071436-29-7 (S)-2-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-2-(4-trifluoromethyl-phenyl)-ethanol 
• 1071436-10-6 (R)-2-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-2-phenyl-ethanol 
• 1071436-05-9 [6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-((R)-1-p-tolyl-ethyl)-amine 
• 1332455-21-6 tert-butyl 2-[6-(biphenyl-4-ylcarbonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]-2,7-diazaspiro[4.5]nonane-7-carboxylate 
• 1332455-29-4 biphenyl-4-yl{4-[4-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl}methanone 
• 1332455-27-2 biphenyl-4-yl{4-[4-(1,3-thiazol-2-yl)piperazin-1-yl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl}methanone 
• 1332455-23-8 tert-butyl 6-[6-(biphenyl-4-ylcarbonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]-2,6-diazaspiro[3,3]heptane-2-carboxylate 
• 1332455-33-0 cis-4-{[6-(biphenyl-4-ylcarbonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]amino}cyclohexanecarboxylic acid 
• 1332455-22-7 ethyl cis-4-{[6-(biphenyl-4-ylcarbonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]amino}cyclohexanecarboxylate 
• 1332455-20-5 biphenyl-4-yl-[4-(3-methoxyazetidin-1-yl)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]methanone 
• 1332455-32-9 biphenyl-4-yl-(4-chloro-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)methanone 
• 1332454-52-0 tert-butyl 2-[6-(biphenyl-4-ylcarbonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]-2,7-diazaspiro[3,5]nonane-7-carboxylate 
• 1332454-29-1 biphenyl-4-yl-[4-(4-methoxypiperidin-1-yl)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]methanone 

Relevant articles and documents

TASK CHANNEL ANTAGONISTS

This invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders

PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF

Fused heterocyclic compounds are provided according to formula 1a or 1b: where R1, R2, and R3 are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.